Covalent Group Awarded $1.1 Million Contract to Study Counter-Bioterrorism Vaccine
WAYNE, Pa. -- Covalent Group, Inc. today announced that it has signed a new contract with DynPort Vaccine Company LLC (DVC) for a Phase I study in the development of a recombinant vaccine designed to provide protection against botulinum neurotoxin. The $1.1 million contract value of this award was included in Covalent's new business announcement dated Dec. 15, 2003.
Botulinum neurotoxins, known primarily for causing cases of foodborne botulism, are produced by the bacterium Clostridium botulinum and the related species Clostridium baratii and Clostridium butyricum. These bacteria produce seven distinct types of botulinum neurotoxins. Most cases of botulism occur when a person swallows a substance that contains the neurotoxin. The neurotoxin then passes through the gastrointestinal tract and into the blood until it eventually reaches peripheral nerve endings where it has the capability to paralyze muscles, including those needed to breathe. The ultimate result can be death.
Kenneth M. Borow, MD, Covalent Group's president and CEO, commented, "We are delighted to begin this relationship with DVC. In the post September 11, 2001 world, a vaccine against botulinum neurotoxins has become a priority as part of our nation's capabilities to fight worldwide terror. Winning this highly competitive bid represents an important step for Covalent Group. Our expertise in the regulatory requirements, conceptualization and design, and operational conduct of vaccine trials is a longstanding strength of our company. Our vaccine capabilities nicely complement our extensive experience in the clinical development of biologics and gene therapy products. Pending the results of the current Phase I study, other clinical trials using this vaccine would be required as part of its overall development program. We look forward to the opportunity of working closely with DVC on this and other vaccine development programs in the future."
DynPort Vaccine Company LLC is a biopharmaceutical company dedicated to the development and licensure of safe and efficacious biodefense vaccines for the U.S. Department of Defense through the Joint Vaccine Acquisition Program (JVAP), and civilian populations. DVC is a joint venture between Computer Sciences Corporation, one of the world's leading information technology (IT) service companies, and Porton International, Inc., a leading vaccine development company focused on the development of biodefense vaccines.
Covalent Group is a clinical research organization that is a leader in the design and management of complex clinical trials for the pharmaceutical, biotechnology and medical device industries.
Source: Covalent Group, Inc.
Newsletter
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
